However, the integration of 7 ICD immunotherapy courses into seven subsequent 5-day TMZ courses, and administration of one IO-Vac® after chemotherapy, in which antigens derived from ICD immunotherapy-induced antigenic extracellular microvesicles and apoptotic bodies were used for loading the DCs, were able to induce measurable reactivity of both CD4 and CD8 T cells against tumor-specific neoepitopes. Here, CD8A is linked to neoplasm.